Prelude Therapeutics Incorporated

PRLD · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders13.8%

Institutions76.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$12.14M	$7.00M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$104.57M	-$139.71M	-$113.73M	-$58.76M
Operating income as a percentage of revenue.	-861.3%	-1995.9%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$99.50M	-$127.17M	-$111.69M	-$56.93M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-1.00	$-2.43	$-4.56
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-1.00	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$35.26M	$12.47M	$31.83M	$218.31M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$141.31M	$175.51M	$305.10M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$72.68M	$44.06M	$19.20M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$68.64M	$131.46M	$285.90M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$56.30M	-$102.89M	-$83.53M	-$46.18M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$67000	$764000	$2.32M	$621000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$56.37M	-$103.65M	-$85.85M	-$46.80M

	You	Peer avg
Revenue Growth	–	-40.5%
ROE	-57.7%	-60.0%

Prelude Therapeutics Incorporated

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Income Statement

Balance Sheet

Cash Flow Statement

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison